Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Anand Ashwin Patel, Adam S. Duvall, Caner Saygin, Howard Weiner, Emily Dworkin, Afsheen Noorani, Jamie Matthews, Rafael Madero Marroquin, Michael W Drazer, Mariam T. Nawas, Gregory W Roloff, Satyajit Kosuri, Michael J. Thirman, Richard A. Larson, Olatoyosi Odenike, Theodore Karrison, Wendy Stock

Blood (2024) 144 (Supplement 1): 1432.

https://doi.org/10.1182/blood-2024-193442

Published: 2024

Journal Articles

Outcomes of BCR::ABL1 -like B-Lineage Acute Lymphoblastic Leukemia in the Era of Novel Therapies

Blood (2024) 144 (Supplement 1): 5918.

https://doi.org/10.1182/blood-2024-208069

Published: 2024

Journal Articles

Impact of Investigational Microbiome Therapeutic SER-155 on Pathogen Domination: Initial Results from a Phase 1b Study in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)

Jonathan U. Peled, Marcel R.M. van den Brink, Doris M. Ponce, Satyajit Kosuri, Nandita Khera, Zachariah DeFilipp, Bina Tejura, David I Lichter, Mary-Jane Lombardo, Meghan Chafee, Jennifer R Wortman, Timothy Straub, Emily Walsh, Augustus Ge, David Lyttle, Brooke Hasson, Christopher Ford, Lisa von Moltke, Matthew Henn

Blood (2023) 142 (Supplement 1): 2198.

https://doi.org/10.1182/blood-2023-188885

Published: 2023

Journal Articles

Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

Blood (2023) 142 (Supplement 1): 3181.

https://doi.org/10.1182/blood-2023-173441

Published: 2023

Journal Articles

Preliminary Safety Results of the Open-Label Phase of a 2-Part Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Cell Transplantation

Doris M. Ponce, Satyajit Kosuri, Nandita Khera, Zachariah Defilipp, David I Lichter, Jonathan U Peled, Marcel R.M. van den Brink, Kelly Brady, Matthew D Puhl, Gabrielle Glick, Brooke Hasson, Barbara H McGovern, Lisa von Moltke, Bina Tejura

Blood (2023) 142 (Supplement 1): 6994.

https://doi.org/10.1182/blood-2023-180119

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies

Blood (2022) 140 (Supplement 1): 10542–10544.

https://doi.org/10.1182/blood-2022-167098

Published: 2022

Journal Articles

Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)

Sameem Abedin, Mehdi Hamadani, Shernan G Holtan, Gary J. Schiller, Molly Gallogly, Edmund K. Waller, Satyajit Kosuri, Sunil H Abhyankar, Sarah M. Anand, Mahasweta Gooptu, Iming Cho, Simona Reed, Shih-Yao Lin, Jesse W Hall, Paul J Martin

Blood (2022) 140 (Supplement 1): 10495–10497.

https://doi.org/10.1182/blood-2022-163027

Published: 2022

Journal Articles

A Phase 1b Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Stem Cell Transplantation

Doris M Ponce, Jonathan U Peled, Bindu Tejura, Christopher Ford, Marcel R M van den Brink, Mary Jane Lombardo, Satyajit Kosuri, Nandita Khera, Zachariah Defilipp, Lisa von Moltke

Blood (2022) 140 (Supplement 1): 10532–10533.

https://doi.org/10.1182/blood-2022-162386

Published: 2022

Journal Articles

Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results

Anand Ashwin Patel, MD, Joseph Heng, MD, Emily Dworkin, PharmD, Sarah Monick, MD, Benjamin A Derman, MD, Sandeep Gurbuxani, MBBS, PhD, Satyajit Kosuri, MD, Hongtao Liu, MD PhD, Michael Thirman, MD, Lucy A. Godley, Olatoyosi Odenike, MD, Richard A. Larson, MD, Wendy Stock, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-138967

Published: 2020

Journal Articles

Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)

Hongtao Liu, MD PhD, Bulent Aydogan, MD, Yasmin Hasan, MD, Amy Wang, MD MPH, Kamil Yenice, MD, Julien Partouche, MD, Wendy Stock, MD, Richard A. Larson, MD, Satyajit Kosuri, MD, James LaBelle, MD PhD, Justin Kline, MD, Peter A. Riedell, MD, Andrew S. Artz, MD, Michael R. Bishop, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-138554

Published: 2020

Journal Articles

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Amy Wang, MD MPH, Justin Kline, MD, Wendy Stock, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Peter A. Riedell, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2019) 134 (Supplement_1): 1956.

https://doi.org/10.1182/blood-2019-123887

Published: 2019

Journal Articles

Outcomes of IDH -Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors

Kirk Cahill, MD, Anand Ashwin Patel, MD, Hongtao Liu, MD PhD, Sandeep Gurbuxani, MBBS, PhD, Michael Thirman, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Wendy Stock, MD, Jeremy Segal, MD PhD, Olatoyosi Odenike, MD

Blood (2019) 134 (Supplement_1): 4176.

https://doi.org/10.1182/blood-2019-122380

Published: 2019

Journal Articles

Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS

Satyajit Kosuri, MD, Sang Mee Lee, PhD, Hongtao Liu, MD PhD, Mylove Mortel, MS, RN, Lucy A Godley, MD PhD, Richard A. Larson, MD, Olatoyosi Odenike, MD, Wendy Stock, MD, Justin Kline, MD, Peter A. Riedell, MD, Koen Van Besien, MD PhD, Michael R. Bishop, MD, Andrew S. Artz, MD

Blood (2019) 134 (Supplement_1): 3324.

https://doi.org/10.1182/blood-2019-126211

Published: 2019

Journal Articles

Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)

Amy Wang, MD MPH, Howard Weiner, Richard A. Larson, MD, Olatoyosi Odenike, MD, Andrew S Artz, MD, Michael R. Bishop, MD, Lucy Godley, MD PhD, Michael Thirman, MD, Satyajit Kosuri, MD, Jane Churpek, MD, Emily K Curran, MD, Kristen Pettit, MD, Wendy Stock, MD, Hongtao Liu, MD PhD

Blood (2018) 132 (Supplement 1): 4073.

https://doi.org/10.1182/blood-2018-99-120244

Published: 2018

Journal Articles

Dose Escalation Prophylactic Donor Lymphocyte Infusion (pDLI) after T-Cell Depleted (TCD) Matched Related Donor (MRD) Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Is Feasible and Results in Higher Donor Chimerism, Faster Immune Re-Constitution and Prolonged PFS

Kothari Shawn, MD, Andrew Artz, MD, Sang Mee Lee, PhD, Noreen Fulton, BS, Jae-Hyun Park, Wendy Stock, MD, Richard A. Larson, MD, Olatoyosi Odenike, MD, Justin Kline, MD, Lucy Godley, MD PhD, James LaBelle, MD PhD, Satyajit Kosuri, MD, Peter A Riedell, MD, Yusuke Nakamura, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2017) 130 (Supplement 1): 4572.

https://doi.org/10.1182/blood.V130.Suppl_1.4572.4572

Published: 2017

Journal Articles

Selinexor Maintenance Is Feasible and Tolerable after Allogeneic Stem Cell Transplant (allo-SCT) for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Hongtao Liu, MD PhD, Andrew Artz, MD, Richard A. Larson, MD, Satyajit Kosuri, MD, Wendy Stock, MD, Michael R. Bishop, MD

Blood (2017) 130 (Supplement 1): 3312.

https://doi.org/10.1182/blood.V130.Suppl_1.3312.3312

Published: 2017

Journal Articles

Comparable Survival and Incidence of Toxicity for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation

Gunjan L. Shah, MDMS, Michael Scordo, MD, Satyajit Kosuri, MD, Diego Adrianzen Herrera, MD, Molly A. Maloy, MS, Jimmy Nieves, RN, Sean Devlin, PhD, Taylor Borrill, CCRP, Scott T. Avecilla, MD PhD, Richard C. Meagher, PhD, Richard J. O'Reilly, MD, Guenther Koehne, MD PhD, Brian C. Shaffer, MD, Miguel-Angel Perales, MD, Boglarka Gyurkocza, MD, Hugo R. Castro-Malaspina, MD, Sergio A. Giralt, MD, Roni Tamari, MD

Blood (2016) 128 (22): 1236.

https://doi.org/10.1182/blood.V128.22.1236.1236

Published: 2016

Journal Articles

A Comprehensive Analysis of Late Toxicities and Associated Risk Factors in Long-Term Survivors of Myeloablative Conditioned Allogeneic Hematopoietic Cell Transplantation Using Ex-Vivo CD34+ Selection-Based Graft-Versus-Host Disease Prophylaxis

Michael Scordo, MD, Gunjan L. Shah, MDMS, Satyajit Kosuri, MD, Diego Adrianzen Herrera, MD, Sean Devlin, PhD, Molly A. Maloy, MS, Jimmy Nieves, RN, Taylor Borrill, CCRP, Scott T. Avecilla, MD PhD, Richard C. Meagher, PhD, Richard J. O'Reilly, MD, Guenther Koehne, MD PhD, Boglarka Gyurkocza, MD, Hugo Castro-Malaspina, MD, Roni Tamari, MD, Miguel Perales, MD, Sergio A. Giralt, MD, Brian C. Shaffer, MD

Blood (2016) 128 (22): 4621.

https://doi.org/10.1182/blood.V128.22.4621.4621

Published: 2016

Journal Articles

An Analysis of Early Toxicities, Associated Risk Factors and Survival during the First Year in Adults Undergoing Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Satyajit Kosuri, MD, Diego Adrianzen Herrera, MD, Michael Scordo, MD, Gunjan Shah, MD M.S., Molly A. Maloy, MS, Sean Devlin, PhD, Jimmy Nieves, RN, Taylor Borrill, CCRP, Scott T. Avecilla, MD PhD, Richard C. Meagher, PhD, Richard J. O'Reilly, MD, Guenther Koehne, MD PhD, Brian C. Shaffer, MD, Boglarka Gyurkocza, MD, Hugo R. Castro-Malaspina, MD, Roni Tamari, MD, Sergio A. Giralt, MD, Miguel Perales, MD

Blood (2016) 128 (22): 2194.

https://doi.org/10.1182/blood.V128.22.2194.2194

Published: 2016

Journal Articles

Wilms´Tumor 1 Protein Is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches

Guenther Koehne, MDPhD, Satyajit Kosuri, MD, Ekaterina Doubrovina, MD PhD, Tao Dao, PhD, Andrew Scott, Achim A Jungbluth, MD, Richard J O'Reilly, MD

Blood (2015) 126 (23): 98.

https://doi.org/10.1182/blood.V126.23.98.98

Published: 2015

NARROW

Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Outcomes of BCR::ABL1 -like B-Lineage Acute Lymphoblastic Leukemia in the Era of Novel Therapies

Impact of Investigational Microbiome Therapeutic SER-155 on Pathogen Domination: Initial Results from a Phase 1b Study in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)

Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

Preliminary Safety Results of the Open-Label Phase of a 2-Part Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies

Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)

A Phase 1b Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Stem Cell Transplantation

Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results

Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Outcomes of IDH -Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors

Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS

Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)

Dose Escalation Prophylactic Donor Lymphocyte Infusion (pDLI) after T-Cell Depleted (TCD) Matched Related Donor (MRD) Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Is Feasible and Results in Higher Donor Chimerism, Faster Immune Re-Constitution and Prolonged PFS

Selinexor Maintenance Is Feasible and Tolerable after Allogeneic Stem Cell Transplant (allo-SCT) for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Comparable Survival and Incidence of Toxicity for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation

A Comprehensive Analysis of Late Toxicities and Associated Risk Factors in Long-Term Survivors of Myeloablative Conditioned Allogeneic Hematopoietic Cell Transplantation Using Ex-Vivo CD34+ Selection-Based Graft-Versus-Host Disease Prophylaxis

An Analysis of Early Toxicities, Associated Risk Factors and Survival during the First Year in Adults Undergoing Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Wilms´Tumor 1 Protein Is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only